ABSTRACT
When the non-profit American Diabetes Association on its website announced that diabetes management involves more than blood sugar control, namely blood pressure and cholesterol control, there was nothing about the best interventions, weight loss and exercise. Rosiglitazone and pioglitazone reduce glucose to the same degree and both increase the risk of heart failure. Both rosiglitazone and pioglitazone increase body weight and fractures, and rosiglitazone have an adverse effect on LDL cholesterol, none of which are related to their effect on glucose. Pioglitazone causes heart failure but is on the market, as it is believed to be safer than rosiglitazone. In July 2010, the Food and Drug Administration (FDA) held a new advisory committee meeting to decide if the drug should remain on the market. Since the 1950s, the FDA has required drug companies to turn over all individual patient case reports from their studies. The asymmetry and lack of consistency in regulatory decision making is dangerous for the patients.
